Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michael Moziak

Physician Assistant Hendersonville, NC Physician Assistant

NPI 1336592872 CMS profile 10719555

800 N Justice St, Hendersonville, NC 28791

Open in the dashboard

General payments

$3,710

129 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Moziak of Hendersonville, NC is reported in the CMS Open Payments database as having received $3,710 across 129 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,473 47
2024 General $810 19
2023 General $879 38
2022 General $147 7
2021 General $401 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Moziak
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Michael Moziak were reported at $1,473. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Michael Moziak Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $401 $132 $37–$438 $132
2022 $147 $155 $48–$522 $149
2023 $879 $167 $52–$557 $160
2024 $810 $178 $55–$600 $164
2025 $1,473 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Forte Bio-Pharma LLC $2,075 37 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $403 29 payments
  3. Collegium Pharmaceutical, Inc. $339 20 payments
  4. Scilex Pharmaceuticals Inc. $262 14 payments
  5. Abbott Laboratories $251 4 payments
  6. Boston Scientific Corporation $221 17 payments
  7. Vertex Pharmaceuticals Incorporated $48 2 payments
  8. AbbVie, Inc. $47 2 payments
  9. Novartis Pharmaceuticals Corporation $18 1 payment
  10. Virtus Pharmaceuticals LLC $18 1 payment
  11. Other $27 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,710 129 payments
Products named General payments · program years 2021–2025
  1. PROLATE Pain $1,875 36 payments
  2. PROLATE Pain $1,875 36 payments
  3. PROLATE Pain $1,875 36 payments
  4. NALOCET Pain $1,875 36 payments
  5. PROLATE Pain $1,141 20 payments
  6. TANLOR $733 16 payments
  7. RELISTOR $376 27 payments
  8. BELBUCA $307 18 payments
  9. ZTLido $262 14 payments
  10. NALOCET Pain $200 1 payment
  11. Other $938 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

4,556

Median for Physician Assistant: 241

Drug cost

$606,948

Median for Physician Assistant: $4,110

Branded share of claims

50.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 604 $190,602
Belbuca Buprenorphine Hcl Brand 142 $107,420
Xtampza Er Oxycodone Myristate Brand 76 $55,716
Buprenorphine Generic 128 $42,978
Relistor Methylnaltrexone Bromide Brand 15 $34,893
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,151 $33,996
Ztlido Lidocaine Brand 37 $32,983
Movantik Naloxegol Oxalate Brand 57 $24,586
Nucynta Tapentadol Hcl Brand 24 $22,707
Oxycodone Hcl Generic 770 $13,433

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$89,426

Medicare's payments for the services billed

Medicare patients

288

Average age 71

Services billed

1,499

188 women, 100 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Depression 35%
Diabetes 32%
Chronic kidney disease 22%
Osteoporosis 22%
Ischemic heart disease 21%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PROLATE
  • Forte Bio-Pharma LLC $509
$509 — —
NALOCET
  • Forte Bio-Pharma LLC $127
$127 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $79
$79 142 —
ZTLido
  • Scilex Pharmaceuticals Inc. $70
$70 37 —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $13
$13 76 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

129 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record